Manila Times Business
NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers
BELTSVILLE, Md., June 04, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, today announced the replay availability for its virtual key opinion leader (KOL) event on SIM0505, held following the Company's ASCO 2026 poster presentation of first reported clinical efficacy data from its Phase 1 dose escalation study (June 1, 2026 press release). SIM0505 is an investigational anti
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Trusted by the Majority of Top 30 U.S. Accounting Firms, Caseware Launches Verity Agentic Pioneer Program
Just now
IperionX Titan DFS Confirms High-Return U.S. Rare Earths and Critical Minerals Project
Just now
Weight Watchers to Increase Access to Comprehensive Weight Loss Options for Patients Nationwide through LillyDirect
Just now
Innovation Labs by Identity Digital Submits DNS-Anchored Durable Identity Proposal for AI Agents to the IETF
Just now